ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Enalapril in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2010-05-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01115946
A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2010-05-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01115985
A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01114230
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2010-04-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 64
- Registration Number
- NCT01104532
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-04-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 23
- Registration Number
- NCT01101906
- Locations
- 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇫🇷Hôpital Henri Mondor, Creteil cedex, France
🇺🇸Tulane University Health Services Center, New Orleans, Louisiana, United States
A Study to Assess Drug-Drug Interaction Between ASP1941 and Miglitol
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2010-06-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 30
- Registration Number
- NCT01099839
A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 15
- Registration Number
- NCT01099345
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 25
- Registration Number
- NCT01097681
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 124
- Registration Number
- NCT01096862
- Locations
- 🇺🇸
Renstar Medical Research, Ocala, Florida, United States
🇺🇸Derm Research, PLLC, Louisville, Kentucky, United States
🇺🇸Palmetto Clinical Trial Services, Greenville, South Carolina, United States
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 547
- Registration Number
- NCT01093534
© Copyright 2024. All Rights Reserved by MedPath